Compare Stocks

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FRE Fremont Gold	C$0.09 -5.6%	C$0.07	C$0.05 ▼ C$0.14	C$3.22M	0.08	23,006 shs	17,050 shs
GNFT Genfit	$3.45 -5.0%	$3.62	$2.89 ▼ $4.75	$171.91M	1.08	15,488 shs	3,488 shs

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FRE Fremont Gold	0.00%	0.00%	+21.43%	+13.33%	0.00%
GNFT Genfit	-4.68%	-5.68%	-1.70%	+3.59%	-7.86%

AI “wealth window” is closing soon! (Ad)

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

I put together this personal video [HERE]…

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
FRE Fremont Gold	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
GNFT Genfit	0.7935 of 5 stars	3.5	3.0	0.0	0.0	0.6	0.0	0.0

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FRE Fremont Gold	N/A	N/A	N/A	N/A
GNFT Genfit	3.00	Buy	$11.00	218.84% Upside

Current Analyst Ratings

Latest GNFT, EI, and FRE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
4/5/2024	GNFT Genfit	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$11.00

(Data available from 4/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FRE Fremont Gold	N/A	N/A	C$0.05 per share	1.84	C$0.05 per share	N/A
GNFT Genfit	$41.31M	4.16	N/A	N/A	$1.48 per share	2.33

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FRE Fremont Gold	-C$2.18M	-C$0.07	N/A	∞	N/A	N/A	-88.32%	-39.85%	N/A
GNFT Genfit	-$31.27M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	7/4/2024 (Estimated)

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
FRE Fremont Gold	N/A	N/A	N/A	N/A	N/A
GNFT Genfit	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FRE Fremont Gold	N/A	0.92	1.79
GNFT Genfit	0.92	2.94	2.94

Ownership

Institutional Ownership

Company	Institutional Ownership
FRE Fremont Gold	1.05%
GNFT Genfit	2.24%

Insider Ownership

Company	Insider Ownership
FRE Fremont Gold	24.72%
GNFT Genfit	4.20%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
FRE Fremont Gold	N/A	37.92 million	N/A	Not Optionable
GNFT Genfit	154	49.83 million	47.74 million	Not Optionable

GNFT, EI, and FRE Headlines

Source	Headline
	GENFIT Annual Combined General Meeting of May 22, 2024 — Availability of Preparatory Documents globenewswire.com - April 15 at 4:10 PM
	GENFIT Announces Publication of the 2023 Universal Registration Document and the 2023 Annual Report on Form 20-F globenewswire.com - April 5 at 2:00 PM
	Genfit's (GNFT) Buy Rating Reiterated at HC Wainwright marketbeat.com - April 5 at 8:28 AM
	GENFIT S.A.: GENFIT Reports Full-Year 2023 Financial Results and Provides Corporate Update finanznachrichten.de - April 5 at 4:56 AM
	GENFIT Reports Full-Year 2023 Financial Results and Provides Corporate Update globenewswire.com - April 4 at 4:10 PM
	European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading msn.com - April 3 at 12:51 PM
	Genfit S.A. (NASDAQ:GNFT) Short Interest Update marketbeat.com - April 2 at 10:00 AM
	European Equities Traded in the US as American Depositary Receipts Rise Slightly in Wednesday Trading msn.com - March 27 at 1:06 PM
	GENFIT Announces Revenues and Cash Position as of December 31, 2023 globenewswire.com - February 29 at 4:10 PM
	GENFIT S.A. thestreet.com - February 25 at 1:21 PM
	Inventiva drops after adverse event in Phase 3 trial for NASH drug msn.com - February 16 at 3:02 PM
	European Equities Traded in the US as American Depositary Receipts Kick Off Week Lower in Monday Trading msn.com - February 5 at 12:50 PM
	European Equities Traded in the US as American Depositary Receipts Trend Lower in Monday Trading msn.com - January 29 at 1:31 PM
	Genfit Stock (NASDAQ:GNFT) Dividends: History, Yield and Dates benzinga.com - December 21 at 3:56 PM
	Genfit SA ADR GNFT morningstar.com - December 20 at 12:33 AM
	FDA grants priority review of Genfit-Ipsen liver disease drug msn.com - December 7 at 7:56 AM
	Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC markets.businessinsider.com - December 7 at 2:56 AM
	GENFIT Highlights ACLF Development Strategy at "ACLF Day" during AASLD The Liver Meeting® 2023 benzinga.com - November 17 at 9:05 AM
	GENFIT Reports Third Quarter 2023 Financial Information finance.yahoo.com - November 9 at 6:14 PM
	Oil Stocks Buoy European Equities Traded in the US as American Depositary Receipts Thursday msn.com - November 9 at 1:13 PM
	Oil Stocks Burden European Equities Traded in the US as American Depositary Receipts Tuesday msn.com - November 7 at 12:41 PM
	GENFIT Announces Publication in Nature Medicine Confirming the Performance of its NASH Diagnostic Technology finance.yahoo.com - September 26 at 8:22 PM
	GENFIT S.A. Unsponsored ADR (GNFT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now finance.yahoo.com - September 26 at 3:22 PM
	GENFIT S.A.: GENFIT Reports First Half-Year 2023 Financial Results and Provides Corporate Update finanznachrichten.de - September 22 at 9:33 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

Viking Therapeutics Surges Sentiment for Triple Threat GLP-1Pill
April 3, 2024 6:20 AM
View Viking Therapeutics Surges Sentiment for Triple Threat GLP-1Pill
3 Cheap Stocks That Shouldn’t Be Cheap for Long
March 26, 2024 9:49 AM
View 3 Cheap Stocks That Shouldn’t Be Cheap for Long
Bargain Alert: AMD is on the Verge of a Massive Catchup Play
April 4, 2024 8:56 AM
View Bargain Alert: AMD is on the Verge of a Massive Catchup Play
UiPath Cuts Q1 and Raises Full Year Guidance
March 26, 2024 7:41 AM
View UiPath Cuts Q1 and Raises Full Year Guidance
PVH Stock Gets 25% Discount: Is Now the Time to Buy?
April 2, 2024 11:25 AM
View PVH Stock Gets 25% Discount: Is Now the Time to Buy?

All Headlines

Company Descriptions

Fremont Gold

CVE:FRE

Fremont Gold Ltd., an exploration stage company, engages in the acquisition, exploration, and evaluation of mineral properties in the United States and Canada. The company explores for gold and copper deposit. The company was formerly known as Palisades Ventures Inc. and changed its name to Fremont Gold Ltd. in June 2017. Fremont Gold Ltd. was incorporated in 2007 and is headquartered in Vancouver, Canada.

Genfit

NASDAQ:GNFT

Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial